305 related articles for article (PubMed ID: 16629850)
1. The rationale for using apoA-I as a clinical marker of cardiovascular risk.
Barter PJ; Rye KA
J Intern Med; 2006 May; 259(5):447-54. PubMed ID: 16629850
[TBL] [Abstract][Full Text] [Related]
2. [Laboratory assessment of HDL heterogeneity and function].
Movva R; Rader DJ
Ann Biol Clin (Paris); 2009; 67(1):7-21. PubMed ID: 19189882
[TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein A-I versus HDL cholesterol in the prediction of risk for myocardial infarction and stroke.
Walldius G; Jungner I
Curr Opin Cardiol; 2007 Jul; 22(4):359-67. PubMed ID: 17556890
[TBL] [Abstract][Full Text] [Related]
4. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence.
Walldius G; Jungner I
J Intern Med; 2006 May; 259(5):493-519. PubMed ID: 16629855
[TBL] [Abstract][Full Text] [Related]
5. Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease.
Moradi H; Pahl MV; Elahimehr R; Vaziri ND
Transl Res; 2009 Feb; 153(2):77-85. PubMed ID: 19138652
[TBL] [Abstract][Full Text] [Related]
6. High-density lipoproteins, inflammation and oxidative stress.
Tabet F; Rye KA
Clin Sci (Lond); 2009 Jan; 116(2):87-98. PubMed ID: 19076062
[TBL] [Abstract][Full Text] [Related]
7. [Advances in apolipoprotein A- I and it's anti-atherosclerosis properties].
Li M; Liu ZM
Sheng Wu Gong Cheng Xue Bao; 2003 Jul; 19(4):387-91. PubMed ID: 15969051
[TBL] [Abstract][Full Text] [Related]
8. Is there a better marker of cardiovascular risk than LDL cholesterol? Apolipoproteins B and A-I--new risk factors and targets for therapy.
Walldius G; Jungner I
Nutr Metab Cardiovasc Dis; 2007 Oct; 17(8):565-71. PubMed ID: 17631989
[TBL] [Abstract][Full Text] [Related]
9. High-density lipoproteins: marker of cardiovascular risk and therapeutic target.
Toth PP; Davidson MH
J Clin Lipidol; 2010; 4(5):359-64. PubMed ID: 21122679
[TBL] [Abstract][Full Text] [Related]
10. Antiinflammatory properties of HDL.
Barter PJ; Nicholls S; Rye KA; Anantharamaiah GM; Navab M; Fogelman AM
Circ Res; 2004 Oct; 95(8):764-72. PubMed ID: 15486323
[TBL] [Abstract][Full Text] [Related]
11. The double jeopardy of HDL.
Navab M; Ananthramaiah GM; Reddy ST; Van Lenten BJ; Ansell BJ; Hama S; Hough G; Bachini E; Grijalva VR; Wagner AC; Shaposhnik Z; Fogelman AM
Ann Med; 2005; 37(3):173-8. PubMed ID: 16019715
[TBL] [Abstract][Full Text] [Related]
12. High-density lipoproteins: an emerging target in the prevention of cardiovascular disease.
Cutri BA; Hime NJ; Nicholls SJ
Cell Res; 2006 Oct; 16(10):799-808. PubMed ID: 17016470
[TBL] [Abstract][Full Text] [Related]
13. High-density lipoproteins in the prevention of cardiovascular disease: changing the paradigm.
Tuteja S; Rader DJ
Clin Pharmacol Ther; 2014 Jul; 96(1):48-56. PubMed ID: 24713591
[TBL] [Abstract][Full Text] [Related]
14. [The role of the high-density lipoprotein (HDL) particle in atherogenesis and potential methods to increase HDL concentrations].
Birjmohun RS; van der Steeg WA; Stroes ES; Kastelein JJ
Ned Tijdschr Geneeskd; 2006 Oct; 150(41):2245-50. PubMed ID: 17076358
[TBL] [Abstract][Full Text] [Related]
15. Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes.
Patel S; Drew BG; Nakhla S; Duffy SJ; Murphy AJ; Barter PJ; Rye KA; Chin-Dusting J; Hoang A; Sviridov D; Celermajer DS; Kingwell BA
J Am Coll Cardiol; 2009 Mar; 53(11):962-71. PubMed ID: 19281927
[TBL] [Abstract][Full Text] [Related]
16. HDL-cholesterol: is it really good? Differences between apoA-I and HDL.
Santos-Gallego CG; Ibanez B; Badimon JJ
Biochem Pharmacol; 2008 Aug; 76(4):443-52. PubMed ID: 18547543
[TBL] [Abstract][Full Text] [Related]
17. Current understanding of the role of high-density lipoproteins in atherosclerosis and senescence.
Nofer JR; Walter M; Assmann G
Expert Rev Cardiovasc Ther; 2005 Nov; 3(6):1071-86. PubMed ID: 16292998
[TBL] [Abstract][Full Text] [Related]
18. The contribution of ApoB and ApoA1 measurements to cardiovascular risk assessment.
Andrikoula M; McDowell IF
Diabetes Obes Metab; 2008 Apr; 10(4):271-8. PubMed ID: 18333887
[TBL] [Abstract][Full Text] [Related]
19. High-density lipoprotein cholesterol-raising strategies.
Kuvin JT; Alsheikh-Ali AA; Karas RH
J Cardiovasc Pharmacol; 2006 Feb; 47(2):196-204. PubMed ID: 16495756
[TBL] [Abstract][Full Text] [Related]
20. Errors that result from using the TC/HDL C ratio rather than the apoB/apoA-I ratio to identify the lipoprotein-related risk of vascular disease.
Sniderman AD; Jungner I; Holme I; Aastveit A; Walldius G
J Intern Med; 2006 May; 259(5):455-61. PubMed ID: 16629851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
